

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 February 2024 (22.02.2024)



(10) International Publication Number
WO 2024/038356 A1

(51) International Patent Classification:

C07D 519/00 (2006.01) C07D 487/10 (2006.01)
C07D 213/64 (2006.01) C07F 5/02 (2006.01)

(21) International Application Number:

PCT/IB2023/058055

(22) International Filing Date:

09 August 2023 (09.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/398,452 16 August 2022 (16.08.2022) US

(71) Applicant: **ARBUTUS BIOPHARMA CORPORATION** [CA/CA]; 25th Floor, 700 West Georgia Street, Vancouver, British Columbia V7Y 1B3 (CA).

(72) Inventors: **COLE, Andrew G.**; 65 Rocky Brook Road, Cranbury, New Jersey 08512 (US). **MASON, Jeremy**; c/o Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, Pennsylvania 18974 (US). **NGUYEN, Duyan**; 106 Cypress Drive, Ambler, Pennsylvania 19002 (US). **OZTURK, Seyma**; 696 Holland Road, Southampton, Pennsylvania 18966 (US). **PALLERLA, Mahesh Kumar**; 811 Long Meadow Drive, Chalfont, Pennsylvania 18914 (US). **PAMULA-PATI, Ganapati Reddy**; 608 Addison Way, Warrington, Pennsylvania 18976 (US). **SPINK, Jan Michelle**; 5 East Mill Road, Hatboro, Pennsylvania 19040 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: SYNTHESIS OF SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS AND SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND ANALOGUES THEREOF



(57) Abstract: The present disclosure includes synthetic methods for preparing certain substituted 1-aryl-1'-heteroaryl and 1,1'-biheteroaryl compounds, which can be used to treat, ameliorate, and/or prevent hepatitis B virus (HBV) infections in a patient, in particular compound 2-((6-(2-chloro-3-(3-chloro-2-(3-methoxy-4-((7-oxo-2,6-diazaspiro[3.4]octan-2-yl)methyl)phenyl)pyridin-4-yl)phenyl)-2-methoxy-pyridin-3-yl)methyl)-2,6-diazaspiro[3.4]octan-7-one.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*